Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy + Pembrolizumab in Advanced Stomach and Esophageal Cancer
NCT06532799Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in gastric cancer (GC), esophageal cancer, sponsored by Essen BioTech. Started Sep 2024; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on NCT06532799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532799.